DUBLIN and BRIDGEWATER, N.J., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN), a company committed to advancing the science of cardiovascular care, today announced it will be presenting new findings at the American Heart Association's Scientific Sessions 2025 scheduled for November 7-10 in New Orleans, Louisiana. These new data supported by Amarin will further reinforce the robust efficacy of VASCEPA®/VAZKEPA® (icosapent ethyl) in cardiovascular risk reduction (CVRR) as well as highl ...